clofibrate has been researched along with cardiovascular agents in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oliver, MF | 1 |
| Banks, T; Oyekan, A | 1 |
1 review(s) available for clofibrate and cardiovascular agents
| Article | Year |
|---|---|
Strategy of reducing coronary risk and the use of drugs.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Cerebrovascular Disorders; Cholesterol; Clofibrate; Coronary Disease; Diuretics; Humans; Hypertension; Information Systems; Lipids; Risk; Thrombosis | 1984 |
1 other study(ies) available for clofibrate and cardiovascular agents
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat.
Topics: Angiotensin II; Animals; Cardiovascular Agents; Clofibrate; Fenofibrate; Hemodynamics; Male; Models, Animal; Nitric Oxide; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 2008 |